At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Zanubrutinib 80 MGdrug
Likely dose
Zanubrutinib 80 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease
In Brief
A Phase 2 clinical trial evaluating Zanubrutinib 80 MG for IgG4 Related Disease. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIgG4 Related Disease
CountriesUnited States
CollaboratorsStanford University
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartAug 2022
Primary CompletionFeb 2025
Study CompletionApr 2025
TodayJul 2026
First PostedOct 26, 2020
Enrollment StartAug 1, 2022
Primary CompletionFeb 11, 2025
Study CompletionApr 3, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.7 years ago
Interventions
Zanubrutinib 80 MGdrug
Zanubrutinib 80 MG for 24 weeks